NASDAQ:AVROAvrobio Stock Price, Forecast & News

Avrobio's stock was trading at $18.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AVRO stock has decreased by 8.4% and is now trading at $16.50.
View which stocks have been most impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Avrobio.

Avrobio is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Avrobio.

Avrobio Inc (NASDAQ:AVRO) issued its quarterly earnings data on Thursday, August, 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.04.
View Avrobio's earnings history.

7 brokerages have issued 1-year price targets for Avrobio's shares. Their forecasts range from $13.00 to $40.00. On average, they anticipate Avrobio's stock price to reach $31.80 in the next year. This suggests a possible upside of 92.7% from the stock's current price.
View analysts' price targets for Avrobio.

News headlines about AVRO stock have trended very positive recently, InfoTrie reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avrobio earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Avrobio.

Avrobio saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 2,710,000 shares, an increase of 12.4% from the July 15th total of 2,410,000 shares. Based on an average trading volume of 335,800 shares, the short-interest ratio is currently 8.1 days. Currently, 9.3% of the company's shares are sold short.
View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Immunovant (IMVT), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Mesoblast (MESO), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), Legend Biotech (PCVX), Bill.com (RVMD), Adverum Biotechnologies (ADVM), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Regenxbio (RGNX), Beam Therapeutics (BEAM), Cortexyme (CRTX) and Coherus Biosciences (CHRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Crispr Therapeutics (CRSP), Agile Therapeutics (AGRX), Amarin (AMRN), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Gilead Sciences (GILD), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Selecta Biosciences (SELB) and Zynerba Pharmaceuticals (ZYNE).

(AVRO) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Avrobio's stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (2.31%), Emerald Mutual Fund Advisers Trust (2.08%), Swiss National Bank (0.17%), Alps Advisors Inc. (0.14%), Trexquant Investment LP (0.11%) and New York State Common Retirement Fund (0.08%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay.
View institutional ownership trends for Avrobio.

AVRO stock was bought by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Monarch Partners Asset Management LLC, Trexquant Investment LP, State Board of Administration of Florida Retirement System, Mitsubishi UFJ Kokusai Asset Management Co. Ltd., and New York State Common Retirement Fund.
View insider buying and selling activity for Avrobio.

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $16.50.

Avrobio has a market capitalization of $594.50 million. The company earns $-72,960,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. Avrobio employs 49 workers across the globe.

The official website for Avrobio is www.avrobio.com.

Avrobio's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]